Clinical Year in Review at #ACR23 By @philseo (@jhrheumatology) Review some of the most impactful scientific studies in #Rheumatology in the past year! 🍕 https://t.co/ystEjzrU8u

My takeaways from #ACR23 #ReviewCourse session on Inflammatory Eye Disease - Dr. Laura Kopplin: 1. Systemic therapy has better long term outcomes than topical treatments, but many/most ophthalmologists are uncomfortable with prescribing there. 2. FAST Trial: Methotrexate better… https://t.co/eoSeWVHsf0

Safety Profile of a JAKi in Patients with RA With up to 6.5 Years of Exposure Long-term JAKi safety data in patients with RA from 6 clinical studies is available to view in the RheumNow virtual poster hall. Sponsored by AbbVie US Medical Affairs. https://t.co/TnCsgxOfCM https://t.co/HEd4NWnuuX

• Safety Profile of a JAKi in Patients with Rheumatoid Arthritis With up to 6.5 Y…

Lupus Nephritis and the Target with PR3+ in proliferative classes with more aggresive phenotype.. #Lupus biopsy.. #ACR23 https://t.co/fGJX57hWx4

Daily Recap - TUESDAY https://t.co/Vq5BSHmPsv

• Dr. John Cush

Latest in Lupus Treatment at #ACR23 • Dr. Dall’Era & Dr. Furie • Approach to Lupus Nephritis 🫘 • Treating Non-Renal SLE / Skin #Lupus #RheumTwitter #Rheumatology https://t.co/sagVipdNJe

Great time at the Knowledge Bowl! Huge thanks to my co-hosts, judges, and amazing #ACR23 staff Congrats to the IGGenerals for taking home the big prize and kudos to ANA 1:40 for the much deserved spirit award! https://t.co/u7bFeQjXeY

ARTIC REWIND RCT 3 yrs csDMARD withdrawal 38% 3yrs csDMARDs free remission vs. 80% stable dose gpe 75% recovery after restart Rx progression 19% in half dose gpe More use bioDMARDs (18%) & GCs (50%) withdraw gpe Trends towards lower infections @RheumNow #ACR23 #ACRBest https://t.co/jhOINV7LLS

Low dose #prednisone has (bad) brain effects. An argument to use steroid sparing drugs in #PMR ⁦@philseo⁩ ⁦@ACRheum⁩ ⁦@RheumNow⁩ #ACR23 THINK about steroid sparing Rx in ?all pts with #PMR #Great #debate https://t.co/usQJRNUN8B

Anterior uveitis incidence across different axSpA treatments Large review and meta-analysis on TNFi, IL-17i, JAKi Immunomodulatory therapy protective against uveitis flare Greatest in TNFi and JAKi @RheumNow #ACR23 Abs# 2550 https://t.co/l3BTL3GuRt

#Lupus #ACR23🦋 🌍A wonderful session unraveling scientific breakthroughs of #CAR T cell therapy 🔥Promising step towards future in revolutionizing Lupus T/t💡📑 💡Keeps efficacy of other vaccines intact! Follow this thread showcasing other imp findings #ACRambassador 1/2 https://t.co/aNFTmJiH0X

✅ Michelle Petri in the VERY FULL #ACR23 early session about #lupus: BEFORE stepping-up with biologics, ask the key questions: -Are you using proton-pump inhibitors (Drug-induced SCLE) -Can I see your sunscreen? -Can I see your hat? -Are you smoking? -Any HCQ blood levels? https://t.co/s73FqyjLOn

#CAR T cells #ACR23 🔥Back to back Sessions on one of the most avidly researched area in Rheum! 💡Check out these slides to understand: ☣️Toxicities and Limitations of CAR T therapy 🆕 Novel CAR designs ⚡️CAR cell sources ❓Research Questions to ponder! #ACRambassador https://t.co/6sOn4rjqY3